Oral Tranexamic Acid for the Treatment of Melasma
Kiran Godse, Rashmi Sarkar, Venkataram Mysore, Manunath M Shenoy, Manas Chatterjee, Rajetha Damisetty, Swapnil Shah, Maya Vedamurthy, Sanjeev Aurangabadkar, Chakravarthi R. Srinivas, Anil Ganjoo, Sudip Das, Anant Patil
Abstract
Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies. Currently, there is no published consensus or guideline document for its use in the treatment of melasma. TXA is available for oral use, topical use as well as an injection. In this article, a consensus of Indian experts is prepared based on the available literature and experience with use of oral TXA in melasma. This review article might help clinicians for use of oral TXA appropriately while treating melasma.